VivoSeq
Hematology

Iron Overload

0

Pipeline Programs↗

0

Active Trials↗

4

Companies Involved↗

Iron Overload is an early-stage landscape with 0 programs across 4 companies. The most active players are Takeda, Novartis, ApoPharma.

Intelligence

Pipeline Metrics

Competitive Density

0/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

69/100

Attrition Rate

29/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Takeda logo

Takeda

0 programs

PreclinicalNovartis logo

Novartis

0 programs

PreclinicalA

ApoPharma

0 programs

PreclinicalF

FerroKin BioSciences, Inc.

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

14

clinical trials

Completed9 · 64%
Terminated3 · 21%
Unknown status1 · 7%
Withdrawn1 · 7%

Clinical Trials

Trial Activity

14 trials

Evaluating Use of Deferasirox as Compared to Deferoxamine in Treating Cardiac Iron Overload
Completed·Novartis logoNovartis·Phase 2·NCT00600938·197 enrolled
Safety and Pharmacodynamic Study of an Oral Iron Chelator Given for 6 Months to Patients With Iron Overload
Completed·Takeda logoTakeda·Phase 2·NCT01186419·51 enrolled
Study Using Deferiprone Alone or in Combination With Desferrioxamine in Iron Overloaded Transfusion-dependent Patients
Completed·LLipomed·Phase 2·NCT00349453·24 enrolled
A Prospective, Mono-center, Interventional Study Evaluating the Effect of One Year Initial Care by Hygieno-dietary Advices With or Without Phlebotomy on Glycemia After at Least 5 Years in Patients With Dysmetabolic Iron Overload Syndrome
Completed·RRennes University Hospital·N/A·NCT03942432·75 enrolled
Safety and Acceptability of Deferiprone Delayed Release Tablets in Patients With Systemic Iron Overload
Completed·AApoPharma·Phase 2·NCT03802916·30 enrolled
Chelation Therapy of Iron Overload With Pyridoxal Isonicotinoyl Hydrazone
Completed·—·Phase 2·NCT00000588·120 enrolled
Safety and Pharmacokinetic Study of Escalating Multiple Doses of an Iron Chelator in Patients With Iron Overload
Completed·FFerroKin BioSciences, Inc.·Phase 1·NCT01039636·20 enrolled
Oral Nifedipine to Treat Iron Overload
Completed·National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)·Phase 1·NCT00712738·6 enrolled
Study With Deferiprone and/or Desferrioxamine in Iron Overloaded Patients
Completed·LLipomed·Phase 3·NCT00350662·95 enrolled
Early and Low Dose Deferasirox (3.5 mg/kg FCT) to Suppress NTBI and LPI as Early Intervention to Prevent Tissue Iron Overload in Lower Risk MDS
Terminated·FFondazione Italiana Sindromi Mielodisplastiche-ETS·Phase 2·NCT03920657·11 enrolled
Study for Transfusionally Iron Overloaded Children, Adolescents and Adults Using FBS0701 (SSP-004184)
Terminated·Takeda logoTakeda·Phase 2·NCT01671111·30 enrolled
Pharmacokinetics of SSP-004184 in the Treatment of Chronic Iron Overload Requiring Chelation Therapy
Terminated·Takeda logoTakeda·Phase 2·NCT01604941·32 enrolled
Treatment of Iron Overload Requiring Chelation Therapy
Withdrawn·Takeda logoTakeda·Phase 2·NCT01927913
Study Of Efficacy,Safety of Combined Deferasirox and Deferiprone Versus Combined Deferiprone and Desferal In Conditions of Iron Overload
Unknown status·—·Phase 2/3·NCT01511848·60 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)